Novoprotein Scientific Inc. Stock Analysis 688137.SS

Suzhou Novoprotein Scientific Co., Ltd. engages in the research and development, production and sales of target and factor proteins, recombinant antibodies, enzymes and reagents. The company is headquartered in Suzhou, Jiangsu and currently employs 566 full-time employees. The company went IPO on 2022-09-29. The Company’s main businesses include the research and development, production and sales of target and factor proteins, recombinant antibodies, enzymes and reagents, and the provision of full process application solutions in the fields of biopharmaceuticals, in vitro diagnostics, and basic research in life sciences. The firm's main products include novel coronavirus diagnostic antibodies, novel coronavirus diagnostic antigens, novel coronavirus pseudoviruses, novel coronavirus non-structural proteins and messenger ribonucleic acid (mRNA) raw materials enzymes and reagents. Its products and services are mainly used in biological medicine, basic research of life science, in vitro diagnosis, mRNA vaccine drugs and other fields. The firm mainly operates its businesses in the domestic and overseas markets.